A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment.